An industry-backed report argues that cancer medicines deliver broader productivity benefits, but the former PBAC chair says productivity gains for most medications were uncertain and considering them could lead to discrimination.
An industry-backed report argues that cancer medicines deliver broader productivity benefits, but the former PBAC chair says productivity gains for most medications were uncertain and considering them could lead to discrimination.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.